BETAAccess all features while we're in beta! Some features may become paid later.Send feedback →
vpside

SCLX

Scilex Holding Co
Nasdaq · Biological products, (no diagnostic substances) (SIC 2836) · FY ends 31 Dec

Revenue, quarterly

$8M−22.8% year on year
$20M$10M$0
Q1 ’22Q1 ’23Q2 ’24Q2 ’25Q2 ’26
Company filings · 10-Q filed 14 Aug 2026 · Q4 = FY − 9Mvpside.com

Gross margin, trailing twelve months

161.1%−15.4 pp year on year
300%200%100%0%
Q4 ’22Q4 ’23Q3 ’24Q3 ’25Q2 ’26
Company filings · 10-Q filed 14 Aug 2026 · TTM = last four quartersvpside.com

Cash and cash equivalents, quarter-end

$566000−86.2% year on year
$40M$20M$0
Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26
Company filings · 10-Q filed 14 Aug 2026 · balance sheet, period-endvpside.com

Free cash flow, trailing twelve months

—
Not reported in this company’s filings
Company filingsvpside.com
Chart 05 is empty
Chart 06 is empty